SCHEMBL10509

SCHEMBL10509

c1n[nH]c2c1CCCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31687184 0.98 KDR (0.41)
SCHEMBL31496664 0.98 KDR (0.41)
Hydrochloric Acid SCHEMBL30801293 0.98 KDR (0.41)
SCHEMBL29649189 0.98 KDR (0.41)
Hydrochloric Acid SCHEMBL30066525 0.98 KDR (0.41)
SCHEMBL4948667 0.98 KDR (0.41)
SCHEMBL400139 0.95
Hydrazine SCHEMBL6036676 0.93 DRD4 (0.40)
Oxalic Acid SCHEMBL572020 0.88 KDM4E (0.40)
SCHEMBL30994991 0.83 TRIM24 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 817 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317753-A9 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2024-09-26 US claimed
CN-115944626-B Application of small molecular compound in preparation of anti-hypoxia or ischemia reperfusion injury drugs 桂林医学院附属医院 2024-04-19 CN claimed
US-20230174538-A1 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2023-06-08 US claimed
CN-114456228-A Substituted glycine-3, 5-difluorophenylalanine peptide derivative and preparation method and application thereof 山东大学 2022-05-10 CN claimed
US-20210253562-A1 ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2021-08-19 US claimed
US-10797249-B2 Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-10-06 US claimed
WO-2020008317-A1 ACYLSUFONAMIDE COMPOUNDS USEFUL AS EP3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2020-01-09 WO claimed
EP-2562294-B1 PLATING BATH AND METHOD ROHM & HAAS ELECT MAT (US) 2019-09-25 EP claimed
US-20180342686-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND SAMSUNG ELECTRONICS CO., LTD. (KR) 2018-11-29 US claimed
EP-2943487-B1 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS GILEAD SCIENCES INC (US) 2016-11-16 EP claimed
EP-1505966-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS Bristol-Myers Squibb Company (US) 2005-02-16 EP claimed
US-20040254158-A1 Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders BRISTOL-MYERS SQUIBB COMPANY 2004-12-16 US claimed
EP-1478624-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2004-11-24 EP claimed
US-6716856-B1 CELL PROLIFERATIVE DISORDERS OR ALZHEIMER'S DISEASE; REDUCED TOXICITY; CDK/CYCLIN KINASE INHIBITORY ACTIVITY PHARMACIA & TUBJOHN SPA (IT) 2004-04-06 US claimed
WO-2003099276-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO claimed
WO-2003068743-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-08-21 WO claimed
JP-2002544271-A 2002-12-24 JP claimed
EP-1177185-A1 4, 5, 6, 7-TETRAHYDROINDAZOLE DERIVATIVES AS ANTITUMOR AGENTS PHARMACIA &amp; UPJOHN S.p.A. (IT) 2002-02-06 EP claimed
WO-2000069846-A1 4,5,6,7-TETRAHYDROINDAZOLE DERIVATIVES AS ANTITUMOR AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2000-11-23 WO claimed
US-5049181-A Novel herbicidally active n-phenyl-azoles CIBA-GEIGY CORPORATION (US) 1991-09-17 US claimed